Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue-associated market (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 18/12/2008
- Report Title: Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue-associated market
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 105
Introduction
Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.
Scope
*Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.
*Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.
*Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.
*Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.
Highlights
Although generic versions of Cephalon's market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).
Despite Xyrem's (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem's sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.
Targeting narcolepsy as a primary indication and then expanding Provigil's label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.
Reasons to Purchase
*Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.
*Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.
*Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication.
Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.
Scope
*Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.
*Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.
*Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.
*Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.
Highlights
Although generic versions of Cephalon's market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).
Despite Xyrem's (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem's sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.
Targeting narcolepsy as a primary indication and then expanding Provigil's label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.
Reasons to Purchase
*Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.
*Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.
*Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
